



09/191,199

March 14, 2000



chain nodes :

15 19

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

7-15 8-19 11-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12  
12-13 13-14

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-15 8-9 8-19 10-11  
10-14 11-12 11-15 12-13 13-14

G1:C,N

G2:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 19:Atom

=> d his

(FILE 'HOME' ENTERED AT 10:11:13 ON 14 MAR 2000)

FILE 'REGISTRY' ENTERED AT 10:11:20 ON 14 MAR 2000

L1 STRUCTURE UPLOADED  
L2 QUE L1  
L3 50 S L2  
L4 1 S INDOLINE/CN

FILE 'STNGUIDE' ENTERED AT 10:16:19 ON 14 MAR 2000

FILE 'REGISTRY' ENTERED AT 10:18:10 ON 14 MAR 2000

FILE 'STNGUIDE' ENTERED AT 10:18:11 ON 14 MAR 2000

FILE 'REGISTRY' ENTERED AT 10:18:36 ON 14 MAR 2000

L5 41018 S NC4-NC5/ES  
L6 1 S L2 SUB=L5 SAM  
L7 1102 S L2 SSS FUL  
L8 5 S L7 AND L5


FILE 'CAPLUS' ENTERED AT 10:25:47 ON 14 MAR 2000

L9 2 S L8  
L10 202 S L7

=> d 12

L2 HAS NO ANSWERS

L1 STR



G1 C,N

G2 O,S,N

Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

=> d bib abs hitstr 19 1-2



L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 2000:117197 CAPLUS

TI 3-Methylidenyl-2-indolinone modulators of protein kinase

IN Tang, Peng Cho; Sun, Li; Miller, Todd Anthony; Liang, Congxin; Tran, Ngoc My; Nguyen, Anh Thi; Nematala, Asaad  
 PA Sugan, Inc., USA  
 SO PCT Int. Appl., 347 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000008202	A2	20000217	WO 1999-US17845	19990804
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1998-129256		19980804		
	US 1998-95470		19980805		
	US 1998-102178		19980928		
	US 1999-116107		19990115		
GI					



AB The title compds. (I) [wherein A = C or N; Q = substituted Ph, pyrrolyl, or indolyl; R0 = H, alkyl, C(O)R19, or C(O)OR19; R1 = H, (un)substituted alkyl, alkoxy, halo, aryl, (CH2)nOC(O)R19, or C(O)NR19; R2 = H, (cyclo)alkyl, (hetero)aryl, heteroalicyclic, trihalomethyl, alkoxy, halo, sulfamido, C(O)OR19, C(O)R19, NHC(O)OR19, (un)substituted amino, etc.; R3 = H, alkyl, trihalomethyl, alkoxy, aryl(oxy), heteroaryl, heteroalicyclic,

OH, halo, sulfamido, C(O)R<sub>19</sub>, (un)substituted amino, etc.; R<sub>4</sub> = H, alkyl, alkoxy, or halo; R<sub>19</sub> = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl; n = 1-4] were prepd. as modulators of the activity of receptor tyrosine kinases (RTKs), non-receptor protein tyrosine kinases (CTKs), and serine/threonine protein kinases (STKs). Examples include over 200 syntheses and data from seventeen bioassays. For instance, II was prepd. by a 3-step sequence involving: (1) cyclization and redn. of 2,4-dinitrophenylacetic acid with SnCl<sub>2</sub>·2H<sub>2</sub>O in EtOH to form 6-amino-2-oxindole, (2) amidation with AcCl in CH<sub>2</sub>Cl<sub>2</sub>, and (3) condensation of the amide with 3,5-diisopropyl-4-methoxybenzaldehyde. II was tested for HER-2 kinase activity (IC<sub>50</sub> = 6.4 .mu.M), cellular proliferation activity as measured by the incorporation of bromodeoxyuridine (BrdU) driven by HER-2 (IC<sub>50</sub> = 9.1 .mu.M) or EGF (IC<sub>50</sub>

=

11 .mu.M), and antitumor activity as measured by growth of SKOV3 ovarian carcinoma cells (IC<sub>50</sub> = 2.6 .mu.M) or A431 human epidermoid carcinoma cells (IC<sub>50</sub> = 2.2 .mu.M). The invention compds. are expected to be useful

in the prevention and treatment of protein kinase related cellular disorders such as cancer, diabetes, hepatic cirrhosis, cardiovascular disease, and immunol. disease.

IT 258831-03-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compd.; prepn. of 3-methylidenyl-2-indolinones as protein kinase modulators for the prevention and treatment of cancer,

diabetes,

hepatic cirrhosis, cardiovascular disease, and immunol. disease)

RN 258831-03-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1999:297422 CAPLUS

DN 130:325139

TI Preparation of arylmethylideneazaoxindoles as protein kinase inhibitors.

IN Cheung, Mui; Glennon, Kimberly Caroline; Lackey, Karen Elizabeth; Peel, Michael Robert

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 135 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9921859	A1	19990506	WO 1998-EP6357	19981008

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,

TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9911510 A1 19990517 AU 1999-11510 19981008  
 PRAI GB 1997-21437 19971010  
 WO 1998-EP6357 19981008  
 OS MARPAT 130:325139  
 GI



AB Title compds. [I; R1 = (substituted) Het, aryl, biaryl; R2-R4 = H, het, fused Het, aryl, alipharyl, cyano, NO2, halo, OR5, SR5, SOR5, NR5R7, COR5,


CO2R5, NR5COR5, CONR5R7, etc.; R5 = H, halo, (substituted) Het, aryl, alipharyl, etc.; R7 = H, R5; Het = (R5 -substituted) acridinyl, benzimidazolyl, benzofuryl, carbazolyl, dithianyl, furyl, imidazolyl, morpholinyl, naphthyridinyl, oxadiazinyl, oxathiazolyl, pyrazolyl, pyridazinyl, quinoxalinyl, tetrazinyl, thiomorpholinyl, thiopyranyl, etc.], were prepd. Thus, 5-bromo-7-azaoxindole (prepn. given), 1-(3,5-dichlorophenyl)pyrrole-2-carboxaldehyde, and 4-methylmorpholine were refluxed in PhMe for 6 h to give 64% 5-bromo-3-[1-(3,5-dichlorophenyl)-1H-pyrrol-2-ylmethylidene]-1,3-dihydropyrrolo[2,3-b]pyridin-2-one. Several I inhibited raf kinase with IC50 < 1 .mu.M.

IT **223645-86-1P 223645-93-0P 223645-94-1P 223645-99-6P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of arylmethylideneazaoxindoles as protein kinase inhibitors)

RN 223645-86-1 CAPLUS


CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 5-bromo-3-[[1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 223645-93-0 CAPLUS


CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 223645-94-1 CAPLUS

CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 3-(2-furanylmethylene)-1,3-dihydro-5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 223645-99-6 CAPLUS

CN 2H-Pyrrolo[2,3-b]pyridin-2-one,  
3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-  
5-(2-furanyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



FILE 'REGISTRY' ENTERED AT 10:11:20 ON 14 MAR 2000  
L1 STRUCTURE UPLOADED  
L2 QUE L1  
L3 50 S L2  
L4 1 S INDOLINE/CN

FILE 'STNGUIDE' ENTERED AT 10:16:19 ON 14 MAR 2000

FILE 'REGISTRY' ENTERED AT 10:18:10 ON 14 MAR 2000

FILE 'STNGUIDE' ENTERED AT 10:18:11 ON 14 MAR 2000

FILE 'REGISTRY' ENTERED AT 10:18:36 ON 14 MAR 2000  
L5 41018 S NC4-NC5/ES  
L6 1 S L2 SUB=L5 SAM  
L7 1102 S L2 SSS FUL  
L8 5 S L7 AND L5

FILE 'CAPLUS' ENTERED AT 10:25:47 ON 14 MAR 2000  
L9 2 S L8  
L10 202 S L7

FILE 'STNGUIDE' ENTERED AT 10:26:51 ON 14 MAR 2000  
L11 0 S NC4-N2C4/ES

FILE 'REGISTRY' ENTERED AT 10:30:48 ON 14 MAR 2000  
L12 1406 S NC4-N2C4/ES  
L13 0 S L7 AND L12  
L14 414865 S NC4-C6/ES  
L15 1097 S L14 AND L7